FDA-ApprovedA

Minoxidil

Minoxidil (Rogaine / Regaine)

The most widely studied hair growth agent with 35+ years of RCT evidence in both men and women.

AEvidence grade

12Claims evaluated

9Key human trials

5 / 5Strength for hair

Mechanism & evidence strength

How Minoxidil works — and how well we know it

Mechanism of action

Minoxidil is a prodrug converted to its active form (minoxidil sulfate) by sulfotransferase enzymes — SULT1A1 in hair follicles (topical) and SULT2A1 in the liver (oral). The active metabolite opens ATP-sensitive potassium channels (Kir6/SUR2), causing cell membrane hyperpolarization. Downstream effects include dose-dependent upregulation of VEGF (up to 6x in dermal papilla cells, driven by the parent drug via HIF-1alpha stabilization) and induction of growth factors (HGF, IGF-1) from dermal papilla cells. Several additional mechanisms are proposed but less well established, including activation of the Wnt/beta-catenin pathway (in-vitro and mouse data, not consistently replicated) and stimulation of prostaglandin E2 synthesis via PGHS-1 (in-vitro data; PGE2's relevance to hair growth in vivo remains unproven). The net effect is prolonged anagen phase, shortened telogen, increased follicular blood supply, and reversal of miniaturization in responsive patients.

Potassium channels (Kir6/SUR2)VEGF upregulationWnt/beta-cateninProstaglandin E2

Route

topical, oral

Typical dose

Topical: 5% solution/foam twice daily. Oral: 0.25–5 mg/day (off-label).

Regulatory status

FDA-approved for androgenetic alopecia (1988). Available as 2% and 5% topical solution/foam.

Best for

First-line topical treatment for male and female pattern hair loss.

Evidence distribution across 12 claims

In Silico—

In Vitro1

In Vivo1

Ex Vivo—

Open-Label4

RCT6

Why the grade is A. Multiple large RCTs spanning 35+ years, FDA-approved.

Efficacy

What the trials actually showed

Key clinical trials for Minoxidil
Study	Design	Population
Olsen 2002 — Topical 5% vs 2% vs Placebo in Men	RCT	393 men (ages 18-49) with androgenetic alopecia
Lucky 2004 — Topical 5% vs 2% vs Placebo in Women	RCT	381 women (ages 18-49) with female pattern hair loss
Olsen 2007 — 5% Foam vs Placebo Foam in Men	RCT	352 men with androgenetic alopecia
Hu 2015 — Combination Finasteride + Minoxidil vs Monotherapy	RCT	450 Chinese men with androgenetic alopecia
Penha 2024 — Oral 5 mg vs Topical 5% in Men (Head-to-Head RCT)	RCT	90 men with androgenetic alopecia
Sinclair 2018 — Low-Dose Oral Minoxidil in Women (FPHL)	OPEN-LABEL	100 women with female pattern hair loss (Sinclair stage 2-5)
Ramos 2020 — Oral Minoxidil 1 mg vs Topical 5% in Women	RCT	Women with female pattern hair loss
Randolph & Tosti 2021 — LDOM Safety Multicenter Study	OBSERVATIONAL	1,404 patients (943 women, 461 men; mean age 43) on LDOM for >=3 months
Dhurat 2013 — Microneedling + Minoxidil vs Minoxidil Alone	RCT	100 men with mild-to-moderate androgenetic alopecia

Olsen 2002 — Topical 5% vs 2% vs Placebo in MenRCT

N: ·
393 men (ages 18-49) with androgenetic alopecia

Endpoint:

Lucky 2004 — Topical 5% vs 2% vs Placebo in WomenRCT

N: ·
381 women (ages 18-49) with female pattern hair loss

Endpoint:

Olsen 2007 — 5% Foam vs Placebo Foam in MenRCT

N: ·
352 men with androgenetic alopecia

Endpoint:

Hu 2015 — Combination Finasteride + Minoxidil vs MonotherapyRCT

N: ·
450 Chinese men with androgenetic alopecia

Endpoint:

Penha 2024 — Oral 5 mg vs Topical 5% in Men (Head-to-Head RCT)RCT

N: ·
90 men with androgenetic alopecia

Endpoint:

Sinclair 2018 — Low-Dose Oral Minoxidil in Women (FPHL)OPEN-LABEL

N: ·
100 women with female pattern hair loss (Sinclair stage 2-5)

Endpoint:

Ramos 2020 — Oral Minoxidil 1 mg vs Topical 5% in WomenRCT

N: ·
Women with female pattern hair loss

Endpoint:

Randolph & Tosti 2021 — LDOM Safety Multicenter StudyOBSERVATIONAL

N: ·
1,404 patients (943 women, 461 men; mean age 43) on LDOM for >=3 months

Endpoint:

Dhurat 2013 — Microneedling + Minoxidil vs Minoxidil AloneRCT

N: ·
100 men with mild-to-moderate androgenetic alopecia

Endpoint:

Time to effect

Initial shedding ('dread shed') commonly occurs at weeks 2-8 as telogen hairs are pushed out by new anagen hairs. Earliest measurable regrowth detectable at week 8 with 5% topical (Olsen 2002). Visible cosmetic improvement typically begins at 2-4 months. Most patients see clear results by 4-6 months.

Peak effect

Topical minoxidil shows a characteristic dissociation between hair count and cosmetic benefit. Nonvellus (terminal) hair count — the primary endpoint in Olsen 2002 — typically peaks early, around weeks 16-26, then slowly declines even with continued use, though counts remain above baseline (5-year follow-up, Olsen 1990). Hair weight and visible density build over roughly 6-12 months and are better maintained long-term (Price 1999). Practically, most cosmetic benefit is established by 6-12 months; this is a maintenance effect, not a cumulative one.

Maintenance

Yes — must continue indefinitely

If stopped

Shedding of minoxidil-dependent hairs begins within about 1-3 months of stopping; in controlled data, hair weight and hair counts returned to placebo levels by roughly 24 weeks (about 6 months) after discontinuation (Price 1999). In earlier observational data, 4 of 10 men fell below their pre-treatment baseline hair counts (Bazzano 1986). Synchronized telogen entry of previously anagen-maintained hairs creates a dramatic shedding event. Minoxidil is a maintenance treatment, not a cure.

Safety profile

Side effects, contraindications, and special populations

FDA black-box warning

Oral minoxidil tablets carry an FDA black box warning (for the antihypertensive indication at 10-40 mg/day): can cause pericardial effusion, occasionally progressing to tamponade, and can exacerbate angina pectoris. Must normally be administered with a beta-blocker and diuretic. This warning was written for hypertensive doses 10-40 mg/day — substantially higher than hair loss doses (0.25-5 mg/day). At hair-loss doses, pericardial effusion was not observed in the largest safety study (Randolph 2021, n=1,404). The black box warning does not apply to topical formulations.

Common adverse events for Minoxidil
Adverse event	Rate	Placebo	Notes
Scalp pruritus/irritation (topical)	6-19% depending on formulation and concentration	—	More common with 5% vs 2% solution. Primarily caused by propylene glycol in solution formulations. 5% foam eliminates propylene glycol and significantly reduces irritation.
Contact dermatitis (topical)	~6.5% for solution formulations	—	Can be allergic or irritant. Patch testing shows propylene glycol is the allergen in ~17% of cases, minoxidil itself in ~5.5%. Switching to foam (propylene glycol-free) or oral resolves most cases.
Hypertrichosis — topical	3-5% (more common in women and with 5%)	—	Facial hypertrichosis reported more in women using topical, especially with solution that drips. Usually resolves 3-4 months after discontinuation.
Hypertrichosis — oral	15.1% overall (Randolph 2021, n=1,404). Dose-dependent: 28.9% at 0.25-0.75 mg/day, 30.4% at 1-1.25 mg/day, 86.8% at 2.5-5 mg/day	—	Most common adverse effect of oral minoxidil. Higher incidence in women. Affects face, arms, legs. Led to discontinuation in only 0.5%. Often manageable with hair removal methods. This is the main tolerability barrier for oral minoxidil.
Initial shedding ('dread shed')	Common but not rigorously quantified; estimated in most patients to some degree	—	Occurs weeks 2-8 as telogen hairs are shed to make way for new anagen hairs. Temporary and actually a sign the drug is working. Not rigorously studied in controlled settings.
Lightheadedness/dizziness (oral)	1.7% (Randolph 2021)	—	Related to vasodilatory mechanism. Dose-dependent. Usually mild and transient.
Fluid retention/peripheral edema (oral)	1.3-10% depending on dose and population (Randolph 2021: 1.3% overall)	—	More common in women. Typically occurs within 1-3 months of starting treatment. Weight gain of 1-2 kg possible. Dose-dependent: 4.0% at 0.25-0.75 mg/day, 10.8% at 1-1.25 mg/day, 34.2% at 2.5-5 mg/day.
Tachycardia/increased heart rate (oral)	0.9% (Randolph 2021)	—	Reflex tachycardia secondary to vasodilation. More common at higher doses. Usually mild at hair-loss doses (0.25-5 mg).
Headache (oral)	0.4% (Randolph 2021)	—	Related to vasodilatory mechanism. Usually transient.
Periorbital edema (oral)	0.3% (Randolph 2021)	—	Mild facial/periorbital puffiness. Dose-dependent. Resolves with discontinuation.

Serious adverse events

Pericardial effusion (oral) (Extremely rare at low doses; no cases in Randolph 2021 (n=1,404). Reported in case reports, mostly linked to compounding errors or higher doses.) — At hypertensive doses (10-40 mg), pericardial effusion was observed in ~3% of patients in early studies. At hair-loss doses (0.25-5 mg), risk appears negligible. More frequently reported in men. May not be strictly dose-dependent. Baseline echocardiogram recommended by some experts before starting oral minoxidil.
Severe hypotension (oral) (Not reported at hair-loss doses in Randolph 2021) — Theoretical risk, especially with concurrent antihypertensives or vasodilators. Blood pressure monitoring recommended when initiating oral minoxidil.
Pleural effusion/anasarca (oral) (Isolated case reports only at low doses) — Extremely rare. Documented in case reports, usually resolving with discontinuation. Pre-existing cardiac or renal conditions may increase risk.
Pet toxicity (topical) — especially cats (Not a human adverse effect, but a documented and increasingly common household hazard: in a 211-animal case series, 8 of 62 symptomatic cats (12.9%) died (Tater 2021).) — Topical minoxidil is highly toxic to pets, especially cats (far more sensitive than dogs). Even a few drops or a single lick can cause hypotension, arrhythmia, pulmonary edema, and death. Pets are exposed by licking the treated scalp or the owner's hands, contact with contaminated pillows or bedding, or drips and splashes. Wash hands immediately after applying, let it dry fully, keep pets away during and after application, and store securely. If exposure is suspected, contact a veterinarian or ASPCA Animal Poison Control (888-426-4435).

Contraindications

Pheochromocytoma (oral) — minoxidil may stimulate catecholamine secretion from the tumor via its antihypertensive action
Pregnancy (FDA Category C) — animal studies show adverse fetal effects; contraindicated in pregnant women
Breastfeeding — minoxidil is excreted in breast milk; not recommended in nursing mothers, especially with preterm or neonatal infants. Topical may pose lower risk to older full-term infants, but caution still advised.
Hypersensitivity to minoxidil or any component of the formulation
Pre-existing pericardial effusion (oral) — risk of worsening fluid accumulation
Significant cardiovascular disease or heart failure (oral) — fluid retention and reflex tachycardia may worsen cardiac status. Careful risk-benefit assessment required.
Pulmonary hypertension secondary to mitral stenosis (oral)

Drug interactions

Guanethidine (Major) — Profound orthostatic hypotension. If starting oral minoxidil, guanethidine must be discontinued 1-3 weeks beforehand. If transition cannot be managed outpatient, hospitalize.
Other antihypertensives (beta-blockers, CCBs, ACE inhibitors, ARBs) (Moderate) — Additive hypotensive effects. Blood pressure monitoring recommended when combining oral minoxidil with antihypertensives. Dose adjustment may be needed.
Other vasodilators (e.g., iloprost, nitrates, PDE5 inhibitors) (Moderate) — Additive vasodilation. Increased risk of hypotension, dizziness, and syncope.
NSAIDs (ibuprofen, naproxen, etc.) (Moderate) — NSAIDs cause sodium and water retention, potentially counteracting minoxidil and its companion diuretic. May also reduce topical minoxidil effectiveness by inhibiting prostaglandin synthesis (PGHS-1 pathway relevant to minoxidil's mechanism).
Low-dose aspirin (Low-Moderate) — Aspirin inhibits SULT1A1 sulfotransferase, the enzyme required to convert topical minoxidil to its active form (minoxidil sulfate). Daily low-dose aspirin may reduce topical minoxidil efficacy. Does not affect oral minoxidil (which uses hepatic SULT2A1).
Corticosteroids and estrogens (Low) — May potentiate fluid retention when combined with oral minoxidil.

Pregnancy

Contraindicated. FDA Pregnancy Category C. Animal studies demonstrate adverse fetal effects including reduced pup survival and developmental abnormalities. No adequate controlled studies in humans. Must not be used during pregnancy.

Women

FDA-approved for topical use in women (2% solution and 5% foam). Topical 5% produces larger absolute hair count gains in women than men (+24.5 vs +18.6 nonvellus hairs/cm²). Hypertrichosis rates higher in women, especially with oral formulations — this is the primary tolerability concern. Oral minoxidil 0.25-2.5 mg is used off-label. Spironolactone is often co-prescribed (Sinclair 2018) both for additive anti-androgen benefit and to counter fluid retention. Women on oral minoxidil must use reliable contraception.

Children

Not FDA-approved for patients under 18. Limited but growing evidence: a systematic review found low-dose oral minoxidil (up to 2.5 mg/day) appears safe in pediatric patients, with hypertrichosis in 12.1% and zero discontinuations due to adverse effects. Used off-label for alopecia areata, loose anagen syndrome, and other pediatric hair disorders. Moderate-to-high doses (3-15 mg/day) carry greater risk, including pericardial effusion (9.5%) and reflex tachycardia — these doses should be avoided.

Evidence breakdown

Every claim, traced back to its source

We took every major claim made about Minoxidil and matched it to the specific experimental model behind it. Click a claim to see the model, the finding, and our assessment of how much weight it deserves.

12 claims · evidence-by-evidence breakdown

RCTWeight: Highest

Topical 5% minoxidil is superior to 2% for regrowing hair in men

Large, well-designed, placebo-controlled RCT published in JAAD. Gold standard evidence. Treatment effect is real and statistically significant.

The experimental model

48-week, double-blind, placebo-controlled RCT of 393 men with AGA (Olsen et al. 2002). Subjects randomized to 5% minoxidil, 2% minoxidil, or placebo twice daily.

The finding

At 48 weeks, 5% produced +18.6 nonvellus hairs/cm², 2% produced +12.7, and placebo +3.9. The 5% concentration showed 45% more regrowth than 2%. Earlier onset of response with 5% (detectable at week 8). More pruritus and local irritation with 5%.

Our assessment

Large, well-designed, placebo-controlled RCT published in JAAD. Gold standard evidence. Treatment effect is real and statistically significant.

Citations

Olsen EA, Dunlap FE, Funicella T, et al (2002)

RCTWeight: Highest

Topical minoxidil works for women — both 2% and 5%

Large, well-designed, placebo-controlled RCT confirming minoxidil efficacy in women. Absolute gains actually larger in women than men in this trial.

The experimental model

48-week, double-blind, placebo-controlled RCT of 381 women with FPHL (Lucky et al. 2004). Randomized to 5%, 2%, or placebo twice daily.

The finding

Mean nonvellus hair count changes at 48 weeks: +24.5 (5%), +20.7 (2%), +9.4 (placebo). Both active treatments significantly outperformed placebo (p<0.001). The 5%/2% difference was smaller in women than in men.

Our assessment

Large, well-designed, placebo-controlled RCT confirming minoxidil efficacy in women. Absolute gains actually larger in women than men in this trial.

Citations

Lucky AW, Piacquadio DJ, Ditre CM, et al (2004)

RCTWeight: Highest

5% minoxidil foam matches solution efficacy with less irritation

Pivotal RCT establishing foam vehicle as equivalent in efficacy while removing the most common irritant. Shorter primary endpoint (16 weeks) but long-term safety data available.

The experimental model

16-week, double-blind, placebo-controlled RCT of 352 men with AGA (Olsen et al. 2007). 5% minoxidil topical foam vs placebo foam. 52-week open-label extension for safety.

The finding

Statistically significant increase in hair counts vs placebo (p<0.0001) and subjective improvement (p<0.0001) at 16 weeks. Foam eliminates propylene glycol, which causes contact dermatitis in ~7% of solution users. Well tolerated over 52 weeks.

Our assessment

Pivotal RCT establishing foam vehicle as equivalent in efficacy while removing the most common irritant. Shorter primary endpoint (16 weeks) but long-term safety data available.

Citations

Olsen EA, Whiting D, Bergfeld W, et al (2007)

In VitroWeight: Low

Minoxidil upregulates VEGF in dermal papilla cells dose-dependently

The experimental model

In vitro — human hair dermal papilla cells treated with minoxidil at concentrations from 0.2 to 24 micromol/L (Lachgar et al. 1998).

The finding

Dose-dependent increase in VEGF mRNA — 24 micromol/L produced 6x more VEGF mRNA than controls. VEGF protein also increased in cell extracts and conditioned media. Supports the hypothesis that minoxidil maintains follicular vascularization.

Our assessment

In vitro data in cultured cells, not in vivo scalp tissue. However, multiple groups have replicated VEGF upregulation, and the effect is driven by the parent minoxidil molecule via HIF-1alpha stabilization — independent of sulfation (Yum 2018). Provides mechanistic support for the clinically proven drug.

Citations

Lachgar S, Charveron M, Gall Y, Bonafe JL (1998)
Yum S, Jeong S, Kim D, et al (2018)

In VivoWeight: Low to Moderate

Minoxidil activates beta-catenin signaling in dermal papilla cells, prolonging anagen

In vitro DPC data tests the right cell type. Mouse in vivo adds support but mouse hair cycling differs from human. Provides molecular explanation for anagen prolongation seen clinically.

The experimental model

In vitro (human dermal papilla cells) + in vivo (mouse topical application). Kwack et al. 2011 measured beta-catenin pathway activation and anagen duration.

The finding

Minoxidil activated beta-catenin transcriptional reporter (pTopflash), induced nuclear beta-catenin accumulation, increased GSK3-beta/PKA/PKB phosphorylation, and upregulated Wnt target genes Axin2 and Lef-1 in human DPCs. Modest anagen extension in mice.

Our assessment

In vitro DPC data tests the right cell type. Mouse in vivo adds support but mouse hair cycling differs from human. Provides molecular explanation for anagen prolongation seen clinically.

Citations

Kwack MH, Kang BM, Kim MK, et al (2011)

Open-LabelWeight: Moderate-High

Sulfotransferase activity predicts minoxidil response — many patients are non-responders

Real human data from plucked follicles measuring a biologically validated enzyme pathway. Explains the well-known clinical observation that many patients fail topical minoxidil. Assay not yet widely a

The experimental model

Human observational + enzyme assay. Roberts et al. 2014 measured SULT1A1 activity in plucked hair follicles and correlated with clinical response in women with AGA.

The finding

Cut-off value of 0.4 OD 405 for low sulfotransferase activity predicted responders with 95% sensitivity and 73% specificity. Women >0.6 AU had meaningfully better results. SULT1A1 was significantly lower in non-responders. An estimated 30-40% of patients may be non-responders.

Our assessment

Citations

Roberts J, Desai N, McCoy J, Bhoyrul S (2014)
Goren A, et al (2015)

RCTWeight: High

Combining minoxidil with finasteride is more effective than either alone

Large (n=450), well-powered comparative trial with 12-month endpoint. Not placebo-controlled but demonstrates clear superiority of combination over monotherapy. Complementary mechanisms well-establish

The experimental model

Human RCT (randomized, comparative). Hu et al. 2015: 450 Chinese men with AGA randomized to finasteride 1 mg (n=160), 5% minoxidil (n=130), or combination (n=160) for 12 months.

The finding

Improvement rates at 12 months: combination 94.1%, finasteride 80.5%, minoxidil 59.0%. Combination produced earlier visible improvement (detectable at 3 months). Adverse reactions rare: finasteride 1.8%, minoxidil 6.1%.

Our assessment

Citations

Hu R, Xu F, Sheng Y, et al (2015)

Open-LabelWeight: Moderate-High

Low-dose oral minoxidil has an acceptable safety profile for hair loss

Largest real-world safety dataset for LDOM. Retrospective, so primarily addresses safety rather than efficacy. Reassuring cardiovascular profile at hair-loss doses (0.25-5 mg/day) vs hypertensive dose

The experimental model

Human multicenter retrospective. Randolph & Tosti 2021: 1,404 patients (943 women, 461 men; mean age 43) on LDOM for at least 3 months across multiple centers.

The finding

Hypertrichosis 15.1% (0.5% discontinued). Systemic effects: lightheadedness 1.7%, fluid retention 1.3%, tachycardia 0.9%, headache 0.4%, periorbital edema 0.3%, insomnia 0.2%. Only 1.7% required discontinuation. No pericardial effusion or serious cardiovascular events at low doses.

Our assessment

Citations

Randolph M, Tosti A (2021)

RCTWeight: Highest

Oral minoxidil 5 mg is comparable to topical 5% for male AGA

First head-to-head RCT of oral vs topical minoxidil, published in a top-tier journal. Establishes oral as a legitimate alternative, not superior. Relatively small sample (n=90) and 24-week endpoint.

The experimental model

Human RCT. Penha et al. 2024: 24-week trial comparing daily oral minoxidil 5 mg with twice-daily topical 5% in 90 men with AGA. Published in JAMA Dermatology.

The finding

No statistically significant difference in terminal hair count increases: frontal +3.1 hairs/cm² difference (p=0.27), total -2.6 hairs/cm² (p=0.32). Photography suggested modest vertex advantage for oral (24% vs 12%) but not significant overall. Hypertrichosis more common with oral.

Our assessment

First head-to-head RCT of oral vs topical minoxidil, published in a top-tier journal. Establishes oral as a legitimate alternative, not superior. Relatively small sample (n=90) and 24-week endpoint.

Citations

Penha MA, Fabbri TR, Weffort F, et al (2024)

RCTWeight: High

Microneedling dramatically boosts minoxidil's effectiveness

Evaluator-blinded RCT with strikingly large effect sizes. Limitations: 12-week duration, single-center, aggressive 1.5 mm needle depth. Subsequent meta-analyses confirm synergy with more modest effect

The experimental model

Human RCT (evaluator-blinded). Dhurat et al. 2013: 100 men with mild-to-moderate AGA randomized to weekly microneedling (1.5 mm) + 5% minoxidil or 5% minoxidil alone for 12 weeks.

The finding

Mean hair count increase: +91.4 (microneedling + minoxidil) vs +22.2 (minoxidil alone) — roughly 4x difference. On 7-point VAS, 40 patients (82%) in microneedling group achieved +2 to +3 response; zero in minoxidil-only group. 82% of microneedling patients reported >50% improvement vs 4.5% for minoxidil only.

Our assessment

Citations

Dhurat R, Sukesh MS, Avhad G, et al (2013)

Open-LabelWeight: Moderate-High

Oral minoxidil works for women, including some topical non-responders

Observational (no placebo) and small comparison trial. But growing clinical experience supports oral as an option for topical non-responders. Hypertrichosis is more common in women on oral, affecting

The experimental model

Human open-label/observational. Sinclair 2018: 100 women with FPHL (Sinclair stage 2-5), oral minoxidil 0.25 mg + spironolactone 25 mg daily for 12 months. Ramos 2019: RCT of oral minoxidil 1 mg vs topical 5% in women, 24 weeks.

The finding

Sinclair 2018: hair loss severity improved 0.85 points at 6 months, 1.3 at 12 months; shedding scores improved 2.3 and 2.6 respectively. Mild side effects in 8 patients. Ramos 2019: oral minoxidil 1 mg increased hair density 12% vs 7.2% for topical (non-significant). Oral may bypass follicular sulfotransferase via hepatic SULT2A1 activation.

Our assessment

Observational (no placebo) and small comparison trial. But growing clinical experience supports oral as an option for topical non-responders. Hypertrichosis is more common in women on oral, affecting adherence.

Citations

Sinclair RD (2018)
Ramos PM, et al (2020)

Open-LabelWeight: High

Stopping minoxidil causes hair loss — sometimes below pre-treatment baseline

Real human data consistent with universal clinical experience. Minoxidil is a maintenance treatment, not a cure. The below-baseline finding is especially important for treatment planning.

The experimental model

Human observational. Discontinuation studies in men on topical minoxidil 2-3% for at least 4 months who stopped treatment and were followed for hair count changes.

The finding

Hair counts approximately doubled on treatment but most recruited hairs were lost upon discontinuation. 4 of 10 men had nonvellus hair counts that fell below pre-treatment baseline. Shedding begins within about 1-3 months of stopping, with hair counts returning to placebo levels by roughly 24 weeks (Price 1999). Synchronized telogen entry of previously anagen-maintained hairs creates a dramatic shedding event.

Our assessment

Real human data consistent with universal clinical experience. Minoxidil is a maintenance treatment, not a cure. The below-baseline finding is especially important for treatment planning.

Citations

Bazzano GS, Terezakis N, Galen W (1986)
Price VH, Menefee E, Strauss PC (1999)

Open questions

What's still missing from the science

No large Phase III RCTs of low-dose oral minoxidil for hair loss — most evidence is retrospective or open-label
No validated, widely available sulfotransferase responder test in routine clinical use, despite a 95%-sensitive assay existing since 2014
No long-term RCT data beyond 48 weeks for topical minoxidil — patients use this drug for decades
No definitive RCT comparing once-daily vs twice-daily 5% topical minoxidil application
Limited cardiac safety data for oral minoxidil beyond 12-24 months in otherwise healthy patients
The 'dread shed' (temporary shedding at weeks 2-8) has not been rigorously quantified in prospective controlled studies
No head-to-head trials establishing optimal microneedling depth and frequency for enhancing minoxidil

Bottom line

Our verdict on Minoxidil

Proven gold standard

Minoxidil is the most extensively studied hair growth agent in the world. Topical 5% has gold-standard RCT evidence showing significant regrowth in both men and women. Oral low-dose minoxidil is rapidly emerging as a legitimate alternative — comparable in efficacy to topical, potentially effective in topical non-responders via a different metabolic activation pathway, but with higher hypertrichosis rates and need for cardiovascular monitoring. The biggest limitation is not efficacy but permanence: stop it, and gains reverse within months. An estimated 30-40% of topical users are partial or non-responders due to low follicular sulfotransferase activity — for these patients, oral minoxidil or combination with finasteride may be the better path.

The most proven topical hair growth treatment available.

How Anagen formulates it

Minoxidil at Anagen

Topical 5% (the most-studied dose), plus oral 2.5 mg / 5 mg for non-responders. The 5% topical is paired with azelaic acid as a mild adjunctive anti-androgen.

TopicalMinoxidil 5% + Azelaic Acid 5%Minoxidil 5%, Azelaic Acid 5%Standard 5% topical minoxidil paired with azelaic acid as a mild adjunctive anti-androgen.$30.00 / mo with a 12-month plan →Oral tabletMinoxidil 2.5 mg tabletsMinoxidil 2.5 mgLow-dose oral minoxidil for users who don't respond to or don't tolerate the topical.$20.00 / mo with a 12-month plan →Oral tabletMINX - Minoxidil 5 mgMinoxidil 5 mgFull-strength oral minoxidil. Reserved for users who tolerate the 2.5 mg dose without side effects.$35.00 / mo with a 12-month plan →TopicalThe Basics Minoxidil 5%, Finasteride 0.1%The two highest-evidence actives in a single topical. The 'if I had to pick one product' option.$30.00 / mo with a 12-month plan →TopicalGuys & GirlsMinoxidil 5%, Liothyronine (T3) 6.5 ng/mL, Levocetirizine 0.5%No-androgen formula — minoxidil + T3 + levocetirizine. Safe across genders and life stages.$35.00 / mo with a 12-month plan →

Take the 60-second quiz →Browse all formulations

Go deeper

Long-form analysis and primary-source breakdowns that go beyond the summary above.

Compare

How does Minoxidil stack up against its closest peers?

FinasterideA

Gold standard oral treatment for male AGA with decades of large RCT data proving it slows loss and regrows hair.

Read the breakdown →

DutasterideB

Most potent 5-alpha reductase inhibitor with RCT evidence of superiority over finasteride.

Read the breakdown →

LatanoprostC

Strong prostaglandin biology and one small positive RCT for scalp, but validated only for eyelash growth (via bimatoprost/Latisse)

Read the breakdown →

← Back to all treatments

FDA-ApprovedA

Minoxidil

Minoxidil (Rogaine / Regaine)

The most widely studied hair growth agent with 35+ years of RCT evidence in both men and women.

AEvidence grade

12Claims evaluated

9Key human trials

5 / 5Strength for hair

Mechanism & evidence strength

How Minoxidil works — and how well we know it

Mechanism of action

Potassium channels (Kir6/SUR2)VEGF upregulationWnt/beta-cateninProstaglandin E2

Route

topical, oral

Typical dose

Topical: 5% solution/foam twice daily. Oral: 0.25–5 mg/day (off-label).

Regulatory status

FDA-approved for androgenetic alopecia (1988). Available as 2% and 5% topical solution/foam.

Best for

First-line topical treatment for male and female pattern hair loss.

Evidence distribution across 12 claims

In Silico—

In Vitro1

In Vivo1

Ex Vivo—

Open-Label4

RCT6

Why the grade is A. Multiple large RCTs spanning 35+ years, FDA-approved.

Efficacy

What the trials actually showed

Key clinical trials for Minoxidil
Study	Design	Population
Olsen 2002 — Topical 5% vs 2% vs Placebo in Men	RCT	393 men (ages 18-49) with androgenetic alopecia
Lucky 2004 — Topical 5% vs 2% vs Placebo in Women	RCT	381 women (ages 18-49) with female pattern hair loss
Olsen 2007 — 5% Foam vs Placebo Foam in Men	RCT	352 men with androgenetic alopecia
Hu 2015 — Combination Finasteride + Minoxidil vs Monotherapy	RCT	450 Chinese men with androgenetic alopecia
Penha 2024 — Oral 5 mg vs Topical 5% in Men (Head-to-Head RCT)	RCT	90 men with androgenetic alopecia
Sinclair 2018 — Low-Dose Oral Minoxidil in Women (FPHL)	OPEN-LABEL	100 women with female pattern hair loss (Sinclair stage 2-5)
Ramos 2020 — Oral Minoxidil 1 mg vs Topical 5% in Women	RCT	Women with female pattern hair loss
Randolph & Tosti 2021 — LDOM Safety Multicenter Study	OBSERVATIONAL	1,404 patients (943 women, 461 men; mean age 43) on LDOM for >=3 months
Dhurat 2013 — Microneedling + Minoxidil vs Minoxidil Alone	RCT	100 men with mild-to-moderate androgenetic alopecia

Olsen 2002 — Topical 5% vs 2% vs Placebo in MenRCT

N: ·
393 men (ages 18-49) with androgenetic alopecia

Endpoint:

Lucky 2004 — Topical 5% vs 2% vs Placebo in WomenRCT

N: ·
381 women (ages 18-49) with female pattern hair loss

Endpoint:

Olsen 2007 — 5% Foam vs Placebo Foam in MenRCT

N: ·
352 men with androgenetic alopecia

Endpoint:

Hu 2015 — Combination Finasteride + Minoxidil vs MonotherapyRCT

N: ·
450 Chinese men with androgenetic alopecia

Endpoint:

Penha 2024 — Oral 5 mg vs Topical 5% in Men (Head-to-Head RCT)RCT

N: ·
90 men with androgenetic alopecia

Endpoint:

Sinclair 2018 — Low-Dose Oral Minoxidil in Women (FPHL)OPEN-LABEL

N: ·
100 women with female pattern hair loss (Sinclair stage 2-5)

Endpoint:

Ramos 2020 — Oral Minoxidil 1 mg vs Topical 5% in WomenRCT

N: ·
Women with female pattern hair loss

Endpoint:

Randolph & Tosti 2021 — LDOM Safety Multicenter StudyOBSERVATIONAL

N: ·
1,404 patients (943 women, 461 men; mean age 43) on LDOM for >=3 months

Endpoint:

Dhurat 2013 — Microneedling + Minoxidil vs Minoxidil AloneRCT

N: ·
100 men with mild-to-moderate androgenetic alopecia

Endpoint:

Time to effect

Peak effect

Maintenance

Yes — must continue indefinitely

If stopped

Safety profile

Side effects, contraindications, and special populations

FDA black-box warning

Common adverse events for Minoxidil
Adverse event	Rate	Placebo	Notes
Scalp pruritus/irritation (topical)	6-19% depending on formulation and concentration	—	More common with 5% vs 2% solution. Primarily caused by propylene glycol in solution formulations. 5% foam eliminates propylene glycol and significantly reduces irritation.
Contact dermatitis (topical)	~6.5% for solution formulations	—	Can be allergic or irritant. Patch testing shows propylene glycol is the allergen in ~17% of cases, minoxidil itself in ~5.5%. Switching to foam (propylene glycol-free) or oral resolves most cases.
Hypertrichosis — topical	3-5% (more common in women and with 5%)	—	Facial hypertrichosis reported more in women using topical, especially with solution that drips. Usually resolves 3-4 months after discontinuation.
Hypertrichosis — oral	15.1% overall (Randolph 2021, n=1,404). Dose-dependent: 28.9% at 0.25-0.75 mg/day, 30.4% at 1-1.25 mg/day, 86.8% at 2.5-5 mg/day	—	Most common adverse effect of oral minoxidil. Higher incidence in women. Affects face, arms, legs. Led to discontinuation in only 0.5%. Often manageable with hair removal methods. This is the main tolerability barrier for oral minoxidil.
Initial shedding ('dread shed')	Common but not rigorously quantified; estimated in most patients to some degree	—	Occurs weeks 2-8 as telogen hairs are shed to make way for new anagen hairs. Temporary and actually a sign the drug is working. Not rigorously studied in controlled settings.
Lightheadedness/dizziness (oral)	1.7% (Randolph 2021)	—	Related to vasodilatory mechanism. Dose-dependent. Usually mild and transient.
Fluid retention/peripheral edema (oral)	1.3-10% depending on dose and population (Randolph 2021: 1.3% overall)	—	More common in women. Typically occurs within 1-3 months of starting treatment. Weight gain of 1-2 kg possible. Dose-dependent: 4.0% at 0.25-0.75 mg/day, 10.8% at 1-1.25 mg/day, 34.2% at 2.5-5 mg/day.
Tachycardia/increased heart rate (oral)	0.9% (Randolph 2021)	—	Reflex tachycardia secondary to vasodilation. More common at higher doses. Usually mild at hair-loss doses (0.25-5 mg).
Headache (oral)	0.4% (Randolph 2021)	—	Related to vasodilatory mechanism. Usually transient.
Periorbital edema (oral)	0.3% (Randolph 2021)	—	Mild facial/periorbital puffiness. Dose-dependent. Resolves with discontinuation.

Serious adverse events

Pericardial effusion (oral) (Extremely rare at low doses; no cases in Randolph 2021 (n=1,404). Reported in case reports, mostly linked to compounding errors or higher doses.) — At hypertensive doses (10-40 mg), pericardial effusion was observed in ~3% of patients in early studies. At hair-loss doses (0.25-5 mg), risk appears negligible. More frequently reported in men. May not be strictly dose-dependent. Baseline echocardiogram recommended by some experts before starting oral minoxidil.
Severe hypotension (oral) (Not reported at hair-loss doses in Randolph 2021) — Theoretical risk, especially with concurrent antihypertensives or vasodilators. Blood pressure monitoring recommended when initiating oral minoxidil.
Pleural effusion/anasarca (oral) (Isolated case reports only at low doses) — Extremely rare. Documented in case reports, usually resolving with discontinuation. Pre-existing cardiac or renal conditions may increase risk.
Pet toxicity (topical) — especially cats (Not a human adverse effect, but a documented and increasingly common household hazard: in a 211-animal case series, 8 of 62 symptomatic cats (12.9%) died (Tater 2021).) — Topical minoxidil is highly toxic to pets, especially cats (far more sensitive than dogs). Even a few drops or a single lick can cause hypotension, arrhythmia, pulmonary edema, and death. Pets are exposed by licking the treated scalp or the owner's hands, contact with contaminated pillows or bedding, or drips and splashes. Wash hands immediately after applying, let it dry fully, keep pets away during and after application, and store securely. If exposure is suspected, contact a veterinarian or ASPCA Animal Poison Control (888-426-4435).

Contraindications

Pheochromocytoma (oral) — minoxidil may stimulate catecholamine secretion from the tumor via its antihypertensive action
Pregnancy (FDA Category C) — animal studies show adverse fetal effects; contraindicated in pregnant women
Breastfeeding — minoxidil is excreted in breast milk; not recommended in nursing mothers, especially with preterm or neonatal infants. Topical may pose lower risk to older full-term infants, but caution still advised.
Hypersensitivity to minoxidil or any component of the formulation
Pre-existing pericardial effusion (oral) — risk of worsening fluid accumulation
Significant cardiovascular disease or heart failure (oral) — fluid retention and reflex tachycardia may worsen cardiac status. Careful risk-benefit assessment required.
Pulmonary hypertension secondary to mitral stenosis (oral)

Drug interactions

Guanethidine (Major) — Profound orthostatic hypotension. If starting oral minoxidil, guanethidine must be discontinued 1-3 weeks beforehand. If transition cannot be managed outpatient, hospitalize.
Other antihypertensives (beta-blockers, CCBs, ACE inhibitors, ARBs) (Moderate) — Additive hypotensive effects. Blood pressure monitoring recommended when combining oral minoxidil with antihypertensives. Dose adjustment may be needed.
Other vasodilators (e.g., iloprost, nitrates, PDE5 inhibitors) (Moderate) — Additive vasodilation. Increased risk of hypotension, dizziness, and syncope.
NSAIDs (ibuprofen, naproxen, etc.) (Moderate) — NSAIDs cause sodium and water retention, potentially counteracting minoxidil and its companion diuretic. May also reduce topical minoxidil effectiveness by inhibiting prostaglandin synthesis (PGHS-1 pathway relevant to minoxidil's mechanism).
Low-dose aspirin (Low-Moderate) — Aspirin inhibits SULT1A1 sulfotransferase, the enzyme required to convert topical minoxidil to its active form (minoxidil sulfate). Daily low-dose aspirin may reduce topical minoxidil efficacy. Does not affect oral minoxidil (which uses hepatic SULT2A1).
Corticosteroids and estrogens (Low) — May potentiate fluid retention when combined with oral minoxidil.

Pregnancy

Women

Children

Evidence breakdown

Every claim, traced back to its source

12 claims · evidence-by-evidence breakdown

RCTWeight: Highest

Topical 5% minoxidil is superior to 2% for regrowing hair in men

Large, well-designed, placebo-controlled RCT published in JAAD. Gold standard evidence. Treatment effect is real and statistically significant.

The experimental model

48-week, double-blind, placebo-controlled RCT of 393 men with AGA (Olsen et al. 2002). Subjects randomized to 5% minoxidil, 2% minoxidil, or placebo twice daily.

The finding

Our assessment

Large, well-designed, placebo-controlled RCT published in JAAD. Gold standard evidence. Treatment effect is real and statistically significant.

Citations

Olsen EA, Dunlap FE, Funicella T, et al (2002)

RCTWeight: Highest

Topical minoxidil works for women — both 2% and 5%

Large, well-designed, placebo-controlled RCT confirming minoxidil efficacy in women. Absolute gains actually larger in women than men in this trial.

The experimental model

48-week, double-blind, placebo-controlled RCT of 381 women with FPHL (Lucky et al. 2004). Randomized to 5%, 2%, or placebo twice daily.

The finding

Our assessment

Large, well-designed, placebo-controlled RCT confirming minoxidil efficacy in women. Absolute gains actually larger in women than men in this trial.

Citations

Lucky AW, Piacquadio DJ, Ditre CM, et al (2004)

RCTWeight: Highest

5% minoxidil foam matches solution efficacy with less irritation

Pivotal RCT establishing foam vehicle as equivalent in efficacy while removing the most common irritant. Shorter primary endpoint (16 weeks) but long-term safety data available.

The experimental model

16-week, double-blind, placebo-controlled RCT of 352 men with AGA (Olsen et al. 2007). 5% minoxidil topical foam vs placebo foam. 52-week open-label extension for safety.

The finding

Our assessment

Pivotal RCT establishing foam vehicle as equivalent in efficacy while removing the most common irritant. Shorter primary endpoint (16 weeks) but long-term safety data available.

Citations

Olsen EA, Whiting D, Bergfeld W, et al (2007)

In VitroWeight: Low

Minoxidil upregulates VEGF in dermal papilla cells dose-dependently

The experimental model

In vitro — human hair dermal papilla cells treated with minoxidil at concentrations from 0.2 to 24 micromol/L (Lachgar et al. 1998).

The finding

Our assessment

Citations

Lachgar S, Charveron M, Gall Y, Bonafe JL (1998)
Yum S, Jeong S, Kim D, et al (2018)

In VivoWeight: Low to Moderate

Minoxidil activates beta-catenin signaling in dermal papilla cells, prolonging anagen

In vitro DPC data tests the right cell type. Mouse in vivo adds support but mouse hair cycling differs from human. Provides molecular explanation for anagen prolongation seen clinically.

The experimental model

In vitro (human dermal papilla cells) + in vivo (mouse topical application). Kwack et al. 2011 measured beta-catenin pathway activation and anagen duration.

The finding

Our assessment

In vitro DPC data tests the right cell type. Mouse in vivo adds support but mouse hair cycling differs from human. Provides molecular explanation for anagen prolongation seen clinically.

Citations

Kwack MH, Kang BM, Kim MK, et al (2011)

Open-LabelWeight: Moderate-High

Sulfotransferase activity predicts minoxidil response — many patients are non-responders

The experimental model

Human observational + enzyme assay. Roberts et al. 2014 measured SULT1A1 activity in plucked hair follicles and correlated with clinical response in women with AGA.

The finding

Our assessment

Citations

Roberts J, Desai N, McCoy J, Bhoyrul S (2014)
Goren A, et al (2015)

RCTWeight: High

Combining minoxidil with finasteride is more effective than either alone

The experimental model

Human RCT (randomized, comparative). Hu et al. 2015: 450 Chinese men with AGA randomized to finasteride 1 mg (n=160), 5% minoxidil (n=130), or combination (n=160) for 12 months.

The finding

Our assessment

Citations

Hu R, Xu F, Sheng Y, et al (2015)

Open-LabelWeight: Moderate-High

Low-dose oral minoxidil has an acceptable safety profile for hair loss

The experimental model

Human multicenter retrospective. Randolph & Tosti 2021: 1,404 patients (943 women, 461 men; mean age 43) on LDOM for at least 3 months across multiple centers.

The finding

Our assessment

Citations

Randolph M, Tosti A (2021)

RCTWeight: Highest

Oral minoxidil 5 mg is comparable to topical 5% for male AGA

First head-to-head RCT of oral vs topical minoxidil, published in a top-tier journal. Establishes oral as a legitimate alternative, not superior. Relatively small sample (n=90) and 24-week endpoint.

The experimental model

Human RCT. Penha et al. 2024: 24-week trial comparing daily oral minoxidil 5 mg with twice-daily topical 5% in 90 men with AGA. Published in JAMA Dermatology.

The finding

Our assessment

First head-to-head RCT of oral vs topical minoxidil, published in a top-tier journal. Establishes oral as a legitimate alternative, not superior. Relatively small sample (n=90) and 24-week endpoint.

Citations

Penha MA, Fabbri TR, Weffort F, et al (2024)

RCTWeight: High

Microneedling dramatically boosts minoxidil's effectiveness

The experimental model

Human RCT (evaluator-blinded). Dhurat et al. 2013: 100 men with mild-to-moderate AGA randomized to weekly microneedling (1.5 mm) + 5% minoxidil or 5% minoxidil alone for 12 weeks.

The finding

Our assessment

Citations

Dhurat R, Sukesh MS, Avhad G, et al (2013)

Open-LabelWeight: Moderate-High

Oral minoxidil works for women, including some topical non-responders

Observational (no placebo) and small comparison trial. But growing clinical experience supports oral as an option for topical non-responders. Hypertrichosis is more common in women on oral, affecting

The experimental model

The finding

Our assessment

Citations

Sinclair RD (2018)
Ramos PM, et al (2020)

Open-LabelWeight: High

Stopping minoxidil causes hair loss — sometimes below pre-treatment baseline

Real human data consistent with universal clinical experience. Minoxidil is a maintenance treatment, not a cure. The below-baseline finding is especially important for treatment planning.

The experimental model

Human observational. Discontinuation studies in men on topical minoxidil 2-3% for at least 4 months who stopped treatment and were followed for hair count changes.

The finding

Our assessment

Real human data consistent with universal clinical experience. Minoxidil is a maintenance treatment, not a cure. The below-baseline finding is especially important for treatment planning.

Citations

Bazzano GS, Terezakis N, Galen W (1986)
Price VH, Menefee E, Strauss PC (1999)

Open questions

What's still missing from the science

No large Phase III RCTs of low-dose oral minoxidil for hair loss — most evidence is retrospective or open-label
No validated, widely available sulfotransferase responder test in routine clinical use, despite a 95%-sensitive assay existing since 2014
No long-term RCT data beyond 48 weeks for topical minoxidil — patients use this drug for decades
No definitive RCT comparing once-daily vs twice-daily 5% topical minoxidil application
Limited cardiac safety data for oral minoxidil beyond 12-24 months in otherwise healthy patients
The 'dread shed' (temporary shedding at weeks 2-8) has not been rigorously quantified in prospective controlled studies
No head-to-head trials establishing optimal microneedling depth and frequency for enhancing minoxidil

Bottom line

Our verdict on Minoxidil

Proven gold standard

The most proven topical hair growth treatment available.

How Anagen formulates it

Minoxidil at Anagen

Topical 5% (the most-studied dose), plus oral 2.5 mg / 5 mg for non-responders. The 5% topical is paired with azelaic acid as a mild adjunctive anti-androgen.